Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could your own blood heal your jaw after a tooth extraction?

NCT ID NCT07585123

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a substance made from a patient's own blood, called platelet-rich fibrin (L-PRF), can prevent a serious condition called jawbone death after tooth extraction. The trial will include 40 people at high risk due to past radiation or certain medications. Half will get L-PRF in the extraction socket, and half will get standard care, with healing checked over a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Platelet-rich fibrin (L-PRF) made from the patient's own blood
What this could lead to
If it works, this could point toward a simple, low-cost way to prevent severe jawbone damage in people who have had radiation or take certain bone medications.
What could go wrong
This is a very small, early feasibility trial with only 40 people. It may not show a clear benefit, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: -General Inclusion Criteria (Applies to All Participants) Age ≥18 years Requiring extraction of one or more teeth with hopeless prognosis Capacity to provide informed consent Ability and willingness to attend all scheduled follow-up visits over 12 months -Post-Radiotherapy Group - Specific Inclusion Previous radiotherapy to the head and neck region Documented radiation dose ≥50 Gy Radiotherapy records (dose, field, date) must be available -Antiresorptive Group - Specific Inclusion Current or prior use of antiresorptive agents (e.g. bisphosphonates or denosumab) Medication history must be available in medical records Exclusion Criteria: * General Exclusion Criteria (Applies to All Participants) Inability to maintain adequate oral hygiene due to motor disability Uncontrolled systemic illness (e.g. uncontrolled diabetes) Use of anticoagulants, immunosuppressants, or medications known to impair healing Requirement for surgical (complex) extractions Enrolment in another clinical trial Known allergy to anaesthetic agents, L-PRF components, or antibiotics used in perioperative protocol Anticipated non-compliance with follow-up -Post-Radiotherapy Group - Specific Exclusion Previous or current antiresorptive therapy History of re-irradiation or radiation dose \<50 Gy -Antiresorptive Group - Specific Exclusion History of head and neck radiotherapy Neoplastic involvement of the jaws Active untreated oral infection or pathology at time of planned extraction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medicine related osteonecrosis of the jaw are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Morriston Hospital

    Swansea, SA6 6NL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.